FindTrial
Sign In

A study to look for the usefulness of BAL test in blood cancer patients with pneumonia.

A prospective observational study to evaluate the clinical utility of staged Broncho alveolar fluid (BAL) analysis in adolescent and adult leukemia and lymphoma patients with febrile neutropenia and lung infiltrates.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/10/016073
Enrollment
120
Registered
2018-10-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C920- Acute myeloblastic leukemia Health Condition 2: C829- Follicular lymphoma, unspecified Health Condition 3: C819- Hodgkin lymphoma, unspecified Health Condition 4: C91- Lymphoid leukemia Health Condition 5: C889- Malignant immunoproliferative disease, unspecified Health Condition 6: C852- Mediastinal (thymic) large B-celllymphoma Health Condition 7: C939- Monocytic leukemia, unspecified Health Condition 8: C859- Non-Hodgkin lymphoma, unspecified Health Condition 9: C948-

Interventions

Intervention1: NIL: NIL

Sponsors

Tata Memorial Centre Research Administrative Council
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged more than or equal to 15years Leukemia and lymphomas on chemotherapy Febrile neutropenia Lung infiltrates on chest x-ray or CT chest

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
The proportion of patients with a confirmed microbiological diagnosis using staged BAL analysisTimepoint: 24 hour—

Secondary

MeasureTime frame
a) The proportion of patients who have a change in antimicrobial therapy. b) The feasibility of doing a Bronchoscopy. c) The proportion of patients who develop major or minor complications during the procedure. d) The 4 and 12week clinical and radiological outcomes. e) The 30-day mortality rates. f) Correlation between radiological and etiological findings. Timepoint: 1)4th week 2)30th Day 3)12th week—

Countries

India

Contacts

Public ContactDr Sweta Bothra

Tata Memorial Centre

dr.hkjain@gmail.com02224177000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026